Systematic Evaluation of Drug-Disease Relationships to Identify Leads for Novel Drug Uses

被引：200

作者：

Chiang, A. P. ^{[1
,2
,3
]}

Butte, A. J. ^{[1
,2
,3
]}

机构：

[1] Stanford Univ, Dept Med, Stanford Ctr Biomed Informat Res, Stanford, CA 94305 USA

[2] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA

[3] Lucile Packard Childrens Hosp, Palo Alto, CA USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 86卷 / 05期

关键词：

INHIBITION; REDUCTASE;

D O I：

10.1038/clpt.2009.103

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug repositioning refers to the discovery of alternative uses for drugs-uses that are different from that for which the drugs were originally intended. One challenge in this effort lies in choosing the indication for which a drug of interest could be prospectively tested. We systematically evaluated a drug treatment-based view of diseases in order to address this challenge. Suggestions for novel drug uses were generated using a "guilt by association" approach. When compared with a control group of drug uses, the suggested novel drug uses generated by this approach were significantly enriched with respect to previous and ongoing clinical trials.

引用

页码：507 / 510

页数：4

共 15 条

[1] Drug repositioning: Identifying and developing new uses for existing drugs [J].